STOCK TITAN
  1. Home
  2. News
  3. AVGR

Avinger Inc - AVGR STOCK NEWS

Welcome to our dedicated news page for Avinger (Ticker: AVGR), a resource for investors and traders seeking the latest updates and insights on Avinger.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avinger's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avinger's position in the market.

News
Avinger Reports Fourth Quarter and Full Year 2023 Results
Rhea-AI Summary
Avinger, Inc. (AVGR) announces a strategic partnership with Zylox-Tonbridge, securing up to $15 million in funding for U.S. growth initiatives and coronary product development. The partnership also opens doors for sales in Asia. Fourth-quarter revenue reaches $1.9 million with a 5% sequential increase, while the gross margin stands at 20%. Expansion of sales team and commercial launch of Tigereye ST and Pantheris LV devices highlight the company's progress. Avinger's President and CEO, Jeff Soinski, expresses enthusiasm for the partnership and outlines strategic benefits for global sales and revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.52%
Tags
earnings
-
News
Avinger to Announce Full Year 2023 Results on March 20, 2024
Rhea-AI Summary
Avinger, Inc. (AVGR) will release its financial results for Q4 and full year 2023 on March 20, 2024. The company, a leader in intravascular image-guided medical devices for vascular disease, will host a conference call for investors and analysts. Details to join the call are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
earnings
-
News
Avinger Announces Strategic Partnership and up to $15 Million Equity Funding Agreement with Zylox-Tonbridge
Rhea-AI Summary
Avinger, Inc. (AVGR) announces a strategic partnership with Zylox-Tonbridge Medical Technology Co., Ltd. to access the Greater China market. The partnership includes a $15 million equity funding, licensing agreement, and technology transfer to expand Avinger's product reach. The deal also involves a three-year extension of existing debt terms, strengthening Avinger's balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.81%
Tags
partnership
News
Avinger Reports Third Quarter 2023 Results
Rhea-AI Summary
Avinger, Inc. reported third-quarter results with revenue of $1.8 million and a gross margin of 21%. They launched the Tigereye ST CTO-crossing device and the Pantheris LV image-guided atherectomy device. They also announced the development of an image-guided coronary CTO-crossing system. Phil Preuss was named Chief Commercial Officer to lead sales force expansion. Avinger plans to increase their direct sales force by more than 25% in Q4. They are making progress on their first coronary product and anticipate filing an IDE application with the FDA by mid-2024. Total revenue decreased compared to the previous quarter, while gross margin and operating expenses remained consistent. Net loss for the quarter was $4.5 million. Cash and cash equivalents totaled $8.7 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
earnings
-
News
Avinger to Announce Third Quarter 2023 Results on October 26
Rhea-AI Summary
Avinger, Inc. to release financial results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
earnings
-
News
Avinger Raises $5.3 Million via At-The-Market Facility
Rhea-AI Summary
Avinger, Inc. strengthens balance sheet by raising $5.3 million through its ATM facility, selling 596,200 shares of common stock at an average price of $8.97. Net proceeds are approximately $5.2 million. The funds will be used for general purposes, including support for Tigereye ST commercial launch and Pantheris LV limited launch program. Avinger is also developing an intravascular image-guided device for coronary artery disease treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.26%
Tags
none
News
Avinger Initiates Full Commercial Launch of Tigereye ST Image-Guided CTO Crossing Device
Rhea-AI Summary
Avinger, Inc. announces full commercial launch of Tigereye ST CTO crossing system
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.8%
Tags
none
-
News
Avinger Announces Presentations by Key Opinion Leaders at AMP (The Amputation Prevention Symposium) 2023
Rhea-AI Summary
Avinger, Inc. presented its Lumivascular technology at The Amputation Prevention Symposium, receiving positive feedback from key opinion leaders. Updated interim data from IMAGE-BTK study shows 96% freedom from target lesion revascularization and 93% patency in limbs treated with Pantheris SV, leading to better outcomes than other technologies. Avinger's products are critical tools for successful revascularization and limb salvage in critical limb ischemia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
none
-
News
Avinger Announces Conversion of 12% of CRG Term Debt into Equity
Rhea-AI Summary
Avinger, Inc. announces the conversion of 12% of its debt into shares of convertible preferred stock. The conversion reduces the debt by $1.92 million. CRG Partners III L.P. holds convertible preferred stock that can be converted into 2,684,160 shares of common stock, representing 19.9% of Avinger's common stock. Each share of convertible preferred stock is initially convertible into 1,398 shares of common stock at a conversion price of $0.715.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
News
Avinger to Announce Second Quarter 2023 Results on July 27
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
earnings
Stock AVGR logo
Avinger Inc

Nasdaq:AVGR

AVGR Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

AVGR Stock Data

5.74M
1.31M
15.85%
5.88%
3.17%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Redwood City

About AVGR

avinger, inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (pad). pad is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. the company’s mission is to radically change the way vascular disease is treated through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. avinger’s current lumivascular products include the lightbox imaging console, the ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or ctos, and pantheris, the first-ever image- guided atherectomy device, designed to precisely remove arterial plaque in pad patients.